Alex N Frickenstein
Overview
Explore the profile of Alex N Frickenstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
88
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang L, Quine S, Frickenstein A, Lee M, Yang W, Sheth V, et al.
Adv Funct Mater
. 2024 Jun;
34(8).
PMID: 38828467
Most nanomedicines require efficient delivery to elicit diagnostic and therapeutic effects. However, en route to their intended tissues, systemically administered nanoparticles often encounter delivery barriers. To describe these barriers, we...
2.
Wang L, Sheth V, Liu K, Panja P, Frickenstein A, He Y, et al.
Adv Mater
. 2024 Apr;
36(28):e2403986.
PMID: 38663008
Cancer nanomedicines predominately rely on transport processes controlled by tumor-associated endothelial cells to deliver therapeutic and diagnostic payloads into solid tumors. While the dominant role of this class of endothelial...
3.
Sheth V, Chen X, Mettenbrink E, Yang W, Jones M, MSaad O, et al.
ACS Nano
. 2023 Apr;
17(9):8376-8392.
PMID: 37071747
Super-resolution microscopy can transform our understanding of nanoparticle-cell interactions. Here, we established a super-resolution imaging technology to visualize nanoparticle distributions inside mammalian cells. The cells were exposed to metallic nanoparticles...
4.
Frickenstein A, Mukherjee S, Harcourt T, He Y, Sheth V, Wang L, et al.
Anal Bioanal Chem
. 2023 Jan;
415(18):4353-4366.
PMID: 36670192
Bioanalytical and biomedical applications often require nanoparticles that exhibit narrow size distributions and biocompatibility. Here, we demonstrate how different synthesis methods affect gold nanoparticle (AuNPs) monodispersity and cytotoxicity. Using single...
5.
Zhang Y, Elechalawar C, Yang W, Frickenstein A, Asfa S, Fung K, et al.
Mater Today (Kidlington)
. 2022 Oct;
56:79-95.
PMID: 36188120
The tumor microenvironment (TME) plays a key role in the poor prognosis of many cancers. However, there is a knowledge gap concerning how multicellular communication among the critical players within...
6.
Yang W, Frickenstein A, Sheth V, Holden A, Mettenbrink E, Wang L, et al.
Nano Lett
. 2022 Sep;
22(17):7119-7128.
PMID: 36048773
We used heparosan (HEP) polysaccharides for controlling nanoparticle delivery to innate immune cells. Our results show that HEP-coated nanoparticles were endocytosed in a time-dependent manner by innate immune cells via...
7.
Donahue N, Sheth V, Frickenstein A, Holden A, Kanapilly S, Stephan C, et al.
Nano Lett
. 2022 May;
22(10):4192-4199.
PMID: 35510841
We report on the absolute quantification of nanoparticle interactions with individual human B cells using quadrupole-based inductively coupled plasma mass spectrometry (ICP-MS). This method enables the quantification of nanoparticle-cell interactions...
8.
Yang W, Wang L, Fang M, Sheth V, Zhang Y, Holden A, et al.
Nano Lett
. 2022 Feb;
22(5):2103-2111.
PMID: 35166110
Nanoparticle modification with poly(ethylene glycol) (PEG) is a widely used surface engineering strategy in nanomedicine. However, since the artificial PEG polymer may adversely impact nanomedicine safety and efficacy, alternative surface...
9.
Frickenstein A, Hagood J, Britten C, Abbott B, McNally M, Vopat C, et al.
Pharmaceutics
. 2021 Apr;
13(4).
PMID: 33920503
Due to the theragnostic potential of mesoporous silica nanoparticles (MSNs), these were extensively investigated as a novel approach to improve clinical outcomes. Boasting an impressive array of formulations and modifications,...
10.
Frickenstein A
Radiol Imaging Cancer
. 2021 Mar;
1(1):e194002.
PMID: 33778674
No abstract available.